Reviewing Axovant Gene Therapies Ltd. (AXGT)’s and Citius Pharmaceuticals Inc. (NASDAQ:CTXR)’s results

Axovant Gene Therapies Ltd. (NASDAQ:AXGT) and Citius Pharmaceuticals Inc. (NASDAQ:CTXR) compete with each other in the Biotechnology sector. We will analyze and compare their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Axovant Gene Therapies Ltd. N/A 0.00 129.06M -10.10 0.00
Citius Pharmaceuticals Inc. N/A 0.00 12.38M -1.06 0.00

Table 1 highlights Axovant Gene Therapies Ltd. and Citius Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the net margins, return on assets and return on equity of Axovant Gene Therapies Ltd. and Citius Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Axovant Gene Therapies Ltd. 0.00% -416% -124.5%
Citius Pharmaceuticals Inc. 0.00% -54.2% -48.3%

Risk & Volatility

Axovant Gene Therapies Ltd. has a 1.16 beta, while its volatility is 16.00% which is more volatile than Standard & Poor’s 500. Citius Pharmaceuticals Inc.’s 8.00% less volatile than Standard & Poor’s 500 volatility due to the stock’s 0.92 beta.

Liquidity

2 and 2 are the respective Current Ratio and a Quick Ratio of Axovant Gene Therapies Ltd. Its rival Citius Pharmaceuticals Inc.’s Current and Quick Ratios are 1.8 and 1.8 respectively. Axovant Gene Therapies Ltd. has a better chance of clearing its pay short and long-term debts than Citius Pharmaceuticals Inc.

Insider and Institutional Ownership

Axovant Gene Therapies Ltd. and Citius Pharmaceuticals Inc. has shares held by institutional investors as follows: 17.9% and 4.2%. Insiders held roughly 58.1% of Axovant Gene Therapies Ltd.’s shares. Insiders Comparatively, held 42.8% of Citius Pharmaceuticals Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Axovant Gene Therapies Ltd. -13.96% -6.25% -18.55% -52.22% -19.21% -0.23%
Citius Pharmaceuticals Inc. 7.27% 0.85% 25.53% -13.24% -53.59% 13.46%

For the past year Axovant Gene Therapies Ltd. had bearish trend while Citius Pharmaceuticals Inc. had bullish trend.

Summary

Citius Pharmaceuticals Inc. beats Axovant Gene Therapies Ltd. on 5 of the 6 factors.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapeutic products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment of catheter related bloodstream infections; and Hydrocortisone-Lidocaine Cream for the treatment of mild to moderate hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.